Results 231 to 240 of about 24,047,971 (353)
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh+5 more
wiley +1 more source
A Scoping Review Mapping Trans* and Gender Diverse People's Representation in Cancer Research. [PDF]
Stirling M+12 more
europepmc +1 more source
Pericytes change function depending on glioblastoma vicinity: emphasis on immune regulation
Pericytes alter their transcriptome depending on their proximity to the tumor core. In the tumor core, pericytes display a more active state with higher communication strength but with lower immune activation potential and a shift toward extracellular matrix production.
Carolina Buizza+5 more
wiley +1 more source
Advancing prostate cancer research: an exploration of periprostatic adipose stem cells. [PDF]
Sacca PA, Calvo JC.
europepmc +1 more source
RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha+10 more
wiley +1 more source
Advances in human microbiome and prostate cancer research. [PDF]
Pei X, Liu L, Han Y.
europepmc +1 more source